Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease

Bibliography

• BELL NJ, BURGET D, HOWDEN CW et al: Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion (1992) 51 (Suppl. 1):59–67.
   Google Scholar
• HATLEBAKK JG, BERSTAD A: Pharmacokinetic optimi-zation in the treatment of gastro-oesophageal reflux disease. Clin. Pharmacokinet. (1996) 31:386–406.
   PubMed Web of Science ®Google Scholar
• CHIBA N, DEGARA CJ, WILKINSON JM, HUNT RH: Speed of healing and symptom relief in grade II to VI gastroe-sophageal reflux disease: a meta-analysis. Gastroenter-ology (1997) 112:1798–1810.
   PubMed Web of Science ®Google Scholar
• HUNT RH: The relationship between the control of pH and healing and symptom relief in gastro-esophageal reflux disease. Aliment. Pharmacol Ther. (1995) 9 (Suppl. 0:3–7.
   Google Scholar
• SANDERS SW: Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibi-tors with other anti-ulcer agents. Clin. Ther. (1996) 18:2-34. Discussion 1.
   Google Scholar
• LAMBERT R: Review article: current practice and futureperspectives in the management of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. (1997) 11:651–662.
   PubMedGoogle Scholar
• SANDMARK S, CARLSSON R, FAUSA 0, LUNDELL L:Omeprazole or ranitidine in the treatment of reflux esophagitis: Results of a double-blind, randomized, Scandinavian multicenter study. Scand. J. Gastroenterol. (1988) 23 (5):625–632.
   PubMed Web of Science ®Google Scholar
• LANGTRY HD, WILDE MI: Omeprazole: a review of itsuse in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs (1998) 56:447–486.
   PubMed Web of Science ®Google Scholar
• LANGTRY HD, WILDE MI: lansoprazole: an update of itspharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs (1997) 54:473–500.
   PubMed Web of Science ®Google Scholar
• NAKAZAWA S, NAMIKI M, MATSUO Y et al.: An evalua-tion of the clinical usefulness of E3810 (rabeprazole sodium) for the treatment of gastric ulcers: comparison with famotidine in a multicenter double-blind study [in Japanese]. Clin. Eval (1993) 21:789–795.
   Google Scholar
• CORINALDESI R, VALENTINI M, BELAICHE J et al.: Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicenter study. Aliment. Pharmacol. Ther. (1995) 9:667–671.
   PubMed Web of Science ®Google Scholar
• DEKKERS CP, BEKER JA, THJODLEIFSSON B et al.: Double-blind, comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment. Pharmacol. Ther. (1999) 13:49–57.
   Google Scholar
• HUMPHRIES TJ, SPERA A, BREITER J et al: Rabeprazole sodium (E3810) once daily is superior to ranitidine 150 mg QID in the healing of erosive or ulcerative gastroesophageal reflux disease. Gastroenterology (1996) 110:A139. Abstract.
   Google Scholar
• MATON PN: Omeprazole. N. Engl. J. Med. (1991) 324 :965–75.
   Google Scholar
• SACHS G, SHIN JM, BRIVING C et al.: The pharmacology of the gastric acid pump: the 1-1±/K+-ATPase. Annu. Rev. Pharmacol. Toxicol. (1995) 35:277–305.
   PubMed Web of Science ®Google Scholar
• SACHS G, PRINZ CK, HERSEY SJ: Acid-related disorders. Mystery to mechanism: mechanism to management. Sushu Publishing, Inc., Palm Beach, FL, USA (1995):72–85.
   Google Scholar
• BESANCON M, SIMOT A, SACHS G, SHIN JM: Sites of reaction of the gastric H,K-ATPase with extracyto-plasmic thiol reagents. J. Biol. Chem. (1997) 272 (36):22438–22446.
   PubMed Web of Science ®Google Scholar
• LAMBRECHT N, CORBETT Z, BAYLE D et al: Identifica-tion of the site of inhibition by omeprazole of 0C-13 fusion protein of the H+K±-ATPase using site directed mutagenesis. J Biol. Chem. (1998) 273:13719–13728.
   PubMed Web of Science ®Google Scholar
• FOUAD YM, KATZ PO, CASTELL DO: Adding ranitidine at bedtime controls nocturnal gastroesophageal reflux (GER) in patients taking proton pump inhibitors twice daily (abstract). Gastroenterology (1999) 118:A208.
   Google Scholar
• FUJISAKI H, MURAKAMI M, FUJIMOTO M et al.: Inhibition of acid secretion by E3810 and omeprazole and their reversal by glutathione. Biochem. Pharmacol. (1991) 42:321–328.
   PubMed Web of Science ®Google Scholar
• JANOWITZ HD, COLCHER H, HOLLANDER F: Inhibitionof gastric secretion in dogs by carbonic anhydrase inhibitor 2-acetyl-amino-1,3,4-thiadiazole-5-sulfonamide. Am. J Physiol. (1952) 171:325–330.
   PubMed Web of Science ®Google Scholar
• PUSCAS I, COLTAU M, BAICAN M et al.: Omeprazole has a dual mechanism of action: it inhibits both H+K+ATPase and gastric mucosa carbonic anhydrase enzyme in humans. J. Pharmacol Exp. Ther. (1999) 290(5):30–34.
   Google Scholar
• MORII M, TAKATA H, FUJISAKI H et al.: The potency of substituted benzimidazoles such as E3810, omepra-zole, Ro 18-5364 to inhibit gastric 1-1±K+ATPase is correlated with the rate of acid activation of the inhibitor. Biochem. Pharmacol (1990) 39:661–667.
   PubMed Web of Science ®Google Scholar
• KROMER W, KRUGER U, HUBER R et al: Differences in pH-dependent activation rates of substituted benzimi-dazoles and biological in vitro correlates. Pharma-cology (1998) 56:57–70.
   Google Scholar
• KROMER W, HORBACH S, LUHMANN R et al.: Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology (1999) 59:57–77.
   PubMed Web of Science ®Google Scholar
• CEDERBERG C, ANDERSSON T et al.: Omeprazole; Pharmacokinetics and metabolism in man. Scand. Gastroenterol (1989) 166 (Suppl.):33–42.
   Google Scholar
• DAMMANN HG, BURKHARDT F: Pantoprazole versus omeprazole. Eur. J. Gastroenterol Hepatol (1999) 1 1:1277–1282.
   Google Scholar
• YASUDA S, OHNISHI A, OGAWA T et al.: Pharmacoki-netic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int. J Clin. Pharmacol. Ther. (1994) 33 (9):466–473.
   Google Scholar
• HERSEY SJ, SACHS G: Gastric acid secretion. Physiol Rev. (1995) 75 (Suppl. 0:155–189.
   Google Scholar
• THOMSON AB, KIRDEIKIS P, LASTIWKA K et al.: Pharma-cokinetics during treatment with omeprazole 20 mg enteric coated tab and 20 mg capsule in asymptomatic duodenal ulcer patients. Can. J. Gastroenterol (1997) 11 (8) :657–660.
   PubMedGoogle Scholar
• LIND T, CEDERBERG C, EKENVED G et al.: Effect ofomeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut (1983) 24:270–276.
   PubMed Web of Science ®Google Scholar
• MULLER P, SEITZ HK, DAMMANN HG et al.: Acid secretion during and after omeprazole treatment in healthy volunteers. Scand. J. Gastroenterol (1986) 21:141–142.
   Web of Science ®Google Scholar
• ROBINSON M, MATON PN, ALLEN MC: Effects of different doses of omeprazole on 24 h esophageal exposure in patients with gastroesophageal reflux. Aliment. Pharmacol. Ther. (1991) 5(6):645–651.
   PubMedGoogle Scholar
• THORING M, HEDENSTROM H, ERIKSSON LS: Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole. Scand. J. Gastroenterol. (1999) 34(3):341–345.
   PubMedGoogle Scholar
• KOOP H, KULY S, FLUG M et al.: 24-hr intragastric pHand 24 hr gastrin profiles during therapy with different doses of the new proton pump inhibitor pantoprazole. Gut (1994) 35 (Suppl. 4):57. Abstract.
   Google Scholar
• SPENCER CM, FAULDS D: lansoprazole. Areappraisal ofits pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid related disorders. Drugs (1994) 48(3)404–430.
   Google Scholar
• TOLMAN KG, SANDERS SW, BUCHI KN et al.: The effects of oral doses of lansoprazole and omeprazole on gastric pH. J. Clin. Gastroenterol (1997) 24:65–70.
   PubMed Web of Science ®Google Scholar
• SHARMA V: Comparison of 24 h intragastric pH using four liquid formulations of lansoprazole and omepra-zole. Am. J. Health Sys. Pharm. (1999) 56 (Suppl. 4):s18–21.
   Google Scholar
• WILLIAMS MP, SERCOMBE J, HAMILTON MI et al.: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-hr intragastric acidity and plasma gastrin concen-trations in young healthy male subjects. Aliment. Pharmcol. Ther. (1998) 12:1079–1089.
   PubMed Web of Science ®Google Scholar
• BLANSHARD C, MILLSON C, SERCOMBE J et al.: Theeffects of rabeprazole on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects [abstract]. Gut (1996) 3 9 (Suppl. 3):A47–48.
   Google Scholar
• ROBINSON M, MATON PN, RODRIGUEZ S et al.: Effects of oral rabeprazole on esophageal and gastric pH in patients with gastroesophageal reflux disease. Aliment. Pharmacol. Ther. (1997) 11:973–980.
   PubMedGoogle Scholar
• ROBINSON M: New Innovation in acid suppression: review of the proton pump inhibitors rabeprazole and pantoprazole. Practical. Gastroenterol. (1 9 9 9) (Suppl.):1–20.
   Google Scholar
• SANDERS S, TOLMAN K, GRESKI PA: The effects oflansoprazole, a new H+K+ATPase inhibitor, on gastric pH and serum gastrin. Aliment. Pharmacol Ther. (1992) 6:359–372.
   PubMedGoogle Scholar
• SAVARINO V, MELA GS, ZENTILIN P et al: Comparison of24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment. Pharmacol. Ther. (1998) 12:1241–1247.
   PubMed Web of Science ®Google Scholar
• HANNAN A, WEIL J, BROOM C et al.: Effects of oralpantoprazole on 24-hour intragastric acidity and plasma gastrin profiles. Aliment. Pharmacol. Ther. (1992) 6:373–380.
   PubMed Web of Science ®Google Scholar
• HUBER R, HARTMANN M, BLIESATH H et al: Pharmacoki-netics of pantoprazole in man. Int. J. Clin. Pharmacol Ther. (1996) 3 4 (Suppl. 0:57–16.
   Google Scholar
• HARTMANN M, THEISS U, HUBER R et al.: Twenty four hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment. Pharmacol Ther. (1996) 10(3):359–366.
   PubMedGoogle Scholar
• SCHOLTZ HE, MEYER BH, LUUS HG: Comparison of the effects of lansoprazole, omeprazole and pantoprazole on 24-hour gastric pH in healthy males. S. Afr. Med. J. (1995) 8:915. Abstract.
   Google Scholar
• REILL L, ERHARDT F, FISCHER R et al.: Effect of oralpantoprazole on 24-hour intragastric pH, serum gastrin profile and drug metabolising enzyme activity in man- a placebo-controlled comparison with r an itidin e . Gut (1993) 34 (4) : Suppl. 63. Abstract.
   Google Scholar
• FRIED R, BEGLINGER C, ROSE K et al: Effects of continuous and pH feedback-controlled iv. pantopra-zole on gastric pH in human volunteers. Gastroenter-ology (1995) 1 08 (Suppl.):A95.
   Google Scholar
• KOOP H, KULY S, FLUG M et al: Comparison of 24-h intragastric pH and 24 hr gastrin profiles during therapy with the proton pump inhibitors pantopra-zole and omeprazole. Gut (1994) 3 5 (Suppl. 4):79. Abstract.
   Google Scholar
• HARDER H, TEYSSEN S, STEPHAN F et al.: Effect of 7-daytherapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects. Scand. J. Gastroenterol (1999) 34 (6) :551–561.
   PubMed Web of Science ®Google Scholar
• PRICHARD PJ, JONES DB, YEOMANS ND et al: The effectiveness of ranitidine in reducing gastric acid secretion decreases with continued therapy. Br. J. Clin. Pharmacol. (1986) 22:663–668.
   PubMed Web of Science ®Google Scholar
• WILDER-SMITH CH, ERNST T, GENNOMI M et al.: Tolerance to oral H2-receptor antagonists. Dig. Dis. Sci. (1990) 35:976–983.
   PubMed Web of Science ®Google Scholar
• LACHMAN L, HOWDEN CW: Twenty-four-hour intragas-tric pH: tolerance within 5 days of continuous ranitidine administration. Am. J. Gastroenterol (2000) 95 (1) :57–61.
   PubMed Web of Science ®Google Scholar
• EL-OMAR E, BENARJEE S, WIRZ A et al: Marked acid rebound hypertension after treatment with ranitidine. Am. J. Gastroenterol. (1996) 91 :355–359.
   PubMedGoogle Scholar
• WEINSTEIN WM, IPPOLITI AF, LEE SW et al.: Acid hypersecretion, parietal cell hyperplasia and endoscopic change after withdrawal oflong-term high dose omeprazole therapy: a prospective study. Gastro-enterology (1996) 11 0 :A294.
   Google Scholar
• WALDUM HL, ARNESTAD JS, BRENNA E et al: Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut (1996) 39:649–653.
   PubMed Web of Science ®Google Scholar
• GILLEN D, WIRZ AA, ARDILL JE, MCCOLL KE: Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology (1999) 116:239–247.
   PubMed Web of Science ®Google Scholar
• LARSSON H, CARLSSON E, RYBERG B, FRYKLUND J, WALLMARK B: Rat parietal cell function after prolonged inhibition of gastric acid secretion. M. J Physiol. (1988) 254:G33–G39.
   Google Scholar
• BLUM RA: Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am. J Health. Syst. Pharm. (1996)5 3 (12):1401–1415.
   Google Scholar
• LANZON-MILLER S, POUNDER RE, HAMILTON MR et al:
   Google Scholar
• h intragastric acidity and gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment. Pharmacol. Ther. (1 9 8 7) 1 (3):239–251.
   Google Scholar
• DEKKERS CP, BEKER JA, THJODLEIFSSON B et al.: Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment. Pharmacol. Ther. (1999) 13:179–186.
   PubMed Web of Science ®Google Scholar
• KLINKENBERG-KNOL EC, NELIS F, DENT J et al.:Long-term omeprazole treatment in resistant gastroe-sophageal reflux disease, efficacy, safety and influence on gastric mucosa. Gastroenterology (2000) 118:661–669.
   PubMed Web of Science ®Google Scholar
• LAMBERTS R, CREUTZFELDT W, STUBER HG, BRUNNERG, SOLCIA E: Long-term omeprazole in peptic ulcer disease: gastrin, endocrine cell growth and gastritis. Gastroenterology (1993) 104:1356–1370.
   PubMed Web of Science ®Google Scholar
• ANDERSSEN T: Pharmacokinetics, metabolism andinteractions of acid pump inhibitors. Clin. Pharmacoki-netics (1996) 31 (1):9–28.
   PubMedGoogle Scholar
• SACHS G: Proton pump inhibitors and acid relateddiseases. Pharmacotherapy (1997) 1 7 (1):22–37.
   Google Scholar
• FURUTA T, OHASHI K, KOSUGE K et al: CYP2C19 genotype status and the effect of omeprazole on intragastric p H in humans. Clin. Pharmacol. Ther. (1999) 65:552–561.
   PubMed Web of Science ®Google Scholar
• SOHN DR, KOBAYASHI K, CHIBAK et al.: Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizer of s-mephenytoin 4'-hydroxylation recruited from an Oriental popula-tion. J. Pharmacol. Exp. Ther. (1992) 1195–202.
   PubMedGoogle Scholar
• CHANG M, TYBRING G, DAHL ML et al.: Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2 C19 . Br. J. Clin. Pharmacol (1995) 39:511–518.
   PubMed Web of Science ®Google Scholar
• ISHIZAKI T, CHIBA K, MANABE K et al.: Comparison ofthe interaction potential of a new proton pump inhibitor, E3810 versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4 '-hydr oxylation. Gun. Pharmacol Ther. (19 9 5) 58:155–64.
   Google Scholar
• HUBER R, HARTMANN M, BLIESATH H: Pharmacoki-netics of pantoprazole in man. j. Clin. Phar. Ther. (1996) 34:186–194.
   Google Scholar
• HOYUMPA AM, TREVINO-ALANIS H, GRIMES I et al: Rabeprazole:pharmacokinetics in patients with stable compensated cirrhosis. Clin. Ther. (1999) 21 (4):691–701.
   PubMedGoogle Scholar
• DELHOTAL-LANDES B, FLOUVAT B, DUCHIER J et al:Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur. j Clin. Pharmacol. (1993) 45:367–371.
   PubMed Web of Science ®Google Scholar
• ORLANDO RC: Reflux esophagitis. In: Textbook of Gastro-enterology. Yamada T (Ed.), JB Lippincott, Philadelphia, PA, USA (1995):1214–1242.
   Google Scholar
• MATHIAS SD, PASTA D, COLWELL H et al.: Assessment ofHRQOL in heartburn patients: results from a community-based crossover study. Gastroenterology (1999) 115:A79. Abstract.
   Google Scholar
• BLUM AL, ADAMI B, BUOZO MH et al.: Effect of cisap rideon relapse of esophagitis. A multinational placebo-controlled trial in patients healed with an antisecre-tory drug. The Italian Eurocis Trialists. Dig. Dis. (1993) 38(3):551–560.
   Google Scholar
• BARDHAN KD, MORRIS P, THOMSON M et al: Omepra-zole in the treatment of erosive esophagitis refractory to high dose cimetidine and ranitidine. Gut (1990) 31 (7):745–749.
   PubMedGoogle Scholar
• VIGNERI S, TERMINI R, LEANDRO G et al.: A Comparison of five maintenance therapies for reflux esophagitis. N Engl. J. Med. (1995) 3 3 3 (17):1106–1110.
   Google Scholar
• ZAGARI M, VILLA KF, FRESTON JW: Proton pump inhibi-tors versus H2-receptor antagonists for the treatment of erosive gastroesophageal reflux disease: a cost-comparative study. Am. J. Managed Care (1995) 1247–255.
   Google Scholar
• HARRIS RA, KUPPERMANN M, RICHTER JE: Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrence of erosive esophagitis: a cost effectiveness analysis. Am. J. Gastroenterol. (1997) 92 (12):2179–2187.
   PubMedGoogle Scholar
• SONTAG SJ: Rolling review: gastroesophageal reflux disease. Aliment. Pharmacol. Ther. (1993) 7:293–312.
   PubMed Web of Science ®Google Scholar
• WILLIAMS MP, SERCOMBE J, HAMILTON MI, POUNDER RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther. (1998) 1 2 (10 :1079–1089.
   Google Scholar
• HARTMANN M, THEISS U, HUBER R et al.: Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment. Pharmacol. Ther. (1996) 10(3):359–366.
   PubMedGoogle Scholar
• FLORENT C, FORESTIER S: Twenty-four-hour monitoring of intragastric activity: comparison between lansoprazole 30 mg and pantoprazole 40 mg. Eur. j Gastroenterol Hepatol. (1997) 9 (2) :195–200.
   PubMedGoogle Scholar
• CASTELL DO, RICHTER JE, ROBINSON M et al.: Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The lansoprazole Group. Am. J Gastroenterol (1996) 91 (9):1749–1757.
   PubMed Web of Science ®Google Scholar
• ISKEDJIAN M, EINARSON TR: Meta-analyses of cisapride, omeprazole and rantidine in the treatment of GORD: implications for treating p atient subgroups. Clin. Drug. Invest. (1998) 1 6 (1):9–18.
   Google Scholar
• HATLEBAKK JG, BERSTAD A, CARLING L et al.:12.nsopra-zole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. Scand. J. Gastroenterof (1993) 28 (3):224–228.
   Google Scholar
• MEE AS, ROWLEY JL: Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment. Pharmacol. Ther. (1 9 9 6) 10 (5):757–763.
   Google Scholar
• MULDER CJ, DEKKER W, GERRETSEN M: lansoprazole 30mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IV (a Dutch multicentre trial). Dutch Study Group. Eur.J. Gastroen-terol. Hepatol (1996) 8(11):1101–1106.
   PubMedGoogle Scholar
• CORINALDESI R, VALENTINI M, BELAICHE J et al.: Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment. Pharmacol. Ther. (1995) 9(6):667–671.
   PubMedGoogle Scholar
• MOSSNER J, HOLSCHER AH, HERZ R et al.: A double-blindstudy of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment. Pharmacol. Ther. (1995) 9(3):321–326.
   PubMedGoogle Scholar
• THJODLEIFSSON BK, DEKKERS CPM, BEKER JA et al.: Rabeprazole 20 mg/day is similar to omeprazole 20 mg/day in the treatment of erosive or ulcerative oesophagitis. Gastroenterology (1997) 112:A312. Abstract.
   Google Scholar
• WATSON RG, THAM TC, JOHNSTON BT et al: Double-blind crossover placebo-controlled study of omepra-zole in the treatment of patients with reflux symptoms and physiological levels of acid reflux-the 'sensitive oesophagus'. Gut (1997) 4 0 (5):587–590.
   Google Scholar
• BATE CM, GRIFFIN SM, KEELING PW et al.: Refluxsymptom relief with omeprazole in patients without unequivocal esophagitis. Aliment. Pharmacol. Ther. (1996) 10(4):547–555.
   PubMedGoogle Scholar
• LIND T, HAVELUND T, CARLSSON R et al.: Heartburnwithout oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand. Gastroenterol (1997) 32(10):974–979.
   PubMed Web of Science ®Google Scholar
• CARLSSON R, DENT J, WATTS R et al.: Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur. J. Gastroenterol. Hepatol. (1998) 1 0 (2):119–124.
   Google Scholar
• VENABLES TL, NEWLAND RD, PATEL AC et al: Omepra-zole 10mg once daily, omeprazole 20mg once daily or ranitidine 150mg twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand. Gastroenterol. (1997) 32(10):965–973.
   PubMed Web of Science ®Google Scholar
• MATON PN, ORLANDO R, JOELSSON B: Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease-a prospective, controlled trial. Aliment. Pharmacol Ther. (1999) 13:819–826.
   PubMedGoogle Scholar
• GALMICHE JP, BARTHELEMY P, HAMELIN B: Tr eating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment. Pharmacol. Ther. (1 9 9 7) 1 1 (4):765–773.
   Google Scholar
• JOHNSSON F, WEYVVADT L, SALHAUG JH: One week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand. J. Gastroenterol. (1998) 33(0:15–20.
   PubMedGoogle Scholar
• BATE CM, RILEY SA, CHAPMAN RWG et al.: Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment. Pharmacol Ther. (1999) 13:59–66.
   PubMed Web of Science ®Google Scholar
• FASS R, OFMAN JJ, GRALNEK IM et al.: Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of Exp. Opin. Pharmacother. (2000) 1(6) gastroesophageal reflux disease. Arch. Intern. Med. (1999) 139:2161–2168.
   Google Scholar
• HAVULAND T, LIND T, WIKLUND I etal.: Quality of live in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am. J Gastroen-terol. (1999) 9 4 (7):1782–1789.
   Google Scholar
• BATE CM, BOOTH SN, CROWE JP: Omeprazole 10mg or 20mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. Gut (1995) 36(4):492–498.
   Google Scholar
• LAURSEN LS, HAVELUND T, BONDESEN S et al.: Omepra-zole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. Scand. J. Gastroenterol. (1995) 30 (9):839–846.
   PubMed Web of Science ®Google Scholar
• CARLSSON R, GALMICHE JP, DENT J et al: Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment. Pharmacol. Ther. (1997) 11 (3) :473–482.
   PubMedGoogle Scholar
• BALDI F, BARDHAN KD, BORMAN BC: lansoprazole maintains healing in patients with reflux esophagitis. Gastroenterology (1996) 110 (Suppl.):55.Abstract.
   Google Scholar
• CARLING L, AXELSSON C, FORSELL H et al.:12.nsoprazole versus omeprazole in long-term maintenance treatment of reflux oesophagitis. A Scandinavian multicentr e trial. Gut (1996) 39 (Suppl. 3) :182.Abstract.
   Google Scholar
• KLINKENBERG-KNOL EC, INTERNATIONAL LONG-TERM OMEPRAZOLE STUDY GROUP: Eleven years' experience of continuous maintenance treatment with omepra-zole in GERD-patients. Gastroenterology (1998) 114 :A180. Abstract.
   Google Scholar
• SILVIS SE, FARAHMAND M, JOHNSON JA et al.: Ar andom-ized blinded comparison of omeprazole and rantidine in the treatment of chronic esophageal stricture secondary to acid peptic esophagitis. Gastrointest. Endosc. (1996) 43(3):216–221.
   PubMedGoogle Scholar
• SMITH PM, KERR GD, COCKEL R et al.: A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenter-ology (1994) 1 07 (5):1312–1318.
   Google Scholar
• NEUMANN CS, IQBAL TH, COOPER BT: Long-term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment. Pharmacol. Ther. (1995) 9(4):451–454.
   PubMedGoogle Scholar
• SHARMA P, SAMPLINER RE, CAMARGO E: Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am. J. Gastroenterof (1997) 92(0582–585.
   PubMed Web of Science ®Google Scholar
• PETERS FTM, GANESH S, KUIPERS EJ et al.: Endoscopic regression of Barrett's esophagus during omeprazole treatment; a randomised double-blind study. Gut (1999) 45 (4):489–494.
   PubMedGoogle Scholar
• BARDHAN KD, LONG R, HAWKEY CJ etal.: lansoprazole, a new proton-pump blocker vs. ranitidine in the treatment of reflux erosive esophagitis. Gastroenter-ology (1991) 1 0 0 (Suppl. 5) :A30. Abstract.
   Google Scholar
• ROBINSON M, SAHBA B, AVNER D etal: A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. Aliment. Pharmacol. Ther. (1995) 9 (0 :25–31.
   PubMedGoogle Scholar
• CORALLO J, VICARI F, FORESTIER S et al.: lansoprazole in acute treatment of reflux esophagitis. Gastroenter-ology (1993) 104:A58. Abstract.
   Google Scholar
• SWARBRICK ET, GOUGH AL, CHRISTIAN J et al.: Preven-tion of recurrence of esophageal stricture. A compara-tive study of lansoprazole and high dose ranitidine. Gastroenterology (1994) 1 06:A189. Abstract.
   Google Scholar
• SANDMARK S, CARLSSON R, FAUSA 0, LUNDELL L: Omeprazole or ranitidine in the treatment of reflux esophagitis. Scand. J. Gastroenterology (1988) 23:625–632.
   PubMed Web of Science ®Google Scholar
• POYNARD T AND THE FRENCH CO-OPERATIVE STUDY GROUP: Fate of patients after healing of oesophagitis. A prospective study of 1030 patients during 6 months. Eur. J. Gastroenterol. Hepatol (1991) 3 (Suppl. 1):S2.
   Google Scholar
• DORSCH E: lansoprazole heals a moderate to severe reflux esophagitis. Am. J. Gastroenterology (1991) 86 A1294. Abstract.
   Google Scholar
• ROBINSON M, LANZA F AND THE LANSOPRAZOLE STUDY GROUP: lansoprazole for one year prevents recurrence of erosive reflux esophagitis. Gastroenter-ology (1994) 106:A166. Abstract.
   Google Scholar
• CLOUD ML, ENAS M, HUMPHRIES TJ et al.: Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig. Dis. Sci. (1998) 43 (5):993–1000.
   PubMedGoogle Scholar
• HUMPHRIES TJ, SPERA A, BREITER J et al: Rabeprazole sodium (E3810) once daily is superior to ranitidine 150 mg q.i.d. in the healing of erosive or ulcerative gastroesophageal reflux disease. Gastroenterology (1996) 110 (Suppl.) :A139. Abstract.
   Google Scholar
• DEKKERS CP, BEKER JA, THJODLEIFSSON B et al.: Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment. Pharmacol. Ther. (1999) 13(1):49–57.
   Google Scholar
• BIRBARA C, BREITER J, COLLINS D et al.: Rabeprazole: preventing endoscopic and symptomatic relapse in erosive or ulcerative GERD. Am. J Gastroenterol. (1998) 93:1630. Abstract.
   Google Scholar
• CAOS A, MOSKOVITZ M, PERDOMO C, NIECESTRO R, HAHNE W: Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Gastroen-terology (1999) 11 6 :A132. Abstract.
   Google Scholar
• HUMPHRIES TJ, DEKKERS CPM, BEKER JA et al.: Rabepra-zole vs. omeprazole for maintenance therapy of healed erosive GERD: results of a 1-year European Exp. Opin. Pharmacother. (2000) 1(6) multicenter trial. Am. J. Gastroenterol. (1998) 93:1616. Abstract.
   Google Scholar
• FLORENT C, FORESTIER S: Twenty-four-hour monitoring of intragastric activity: comparison between lansoprazole 30 mg and pantoprazaole 40 mg. Eur.J. Gastroenterol. Hepatol (1997) 9(2):195–200.
   PubMedGoogle Scholar
• DETTMER A, VOGT R, SIELAFF F, LUHMANN R et al: Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Aliment. Pharmacol. Ther. (1998) 1 2 (9):865–872.
   Google Scholar
• KOOP H, SCHEPP W, DAMMANN HG et al.: Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis: results of a German multicenter study. J. Clin. Gastroenterol. (1995) 20(3):192–195.
   PubMedGoogle Scholar
• MOSSNER J, HOLSCHER AH, HERZ R, SCHNEIDER A: A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment. Pharmacol Ther. (1995) 9(3):321–326.
   PubMedGoogle Scholar
• JASPERSEN D, DIEHL K-L, SCHOEPPNER H, GEYER P, MARTENS E: A comparison of omeprazole, lansopra-zole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Aliment. Pharmacol. Ther. (1998) 1 2 (1):49–52.
   Google Scholar
• MOSSNER J, KOOP H, PORST H, WUBBOLDING H, SCHNEIDER A, MATER C: One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. Aliment. Pharmacol. Ther. (1997) 11 (6) :1087–1092.
   PubMedGoogle Scholar
• VAN RENSBERG CJ, HONIBALL PJ, VAN ZYL JH et al: Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux esophagitis - a 2-year follow-up. Aliment. Pharmacol. Ther. (1999) 13(8):1023–1028.
   PubMedGoogle Scholar
• RICHTER JE: Ex traesophageal manifestations of gastroesophageal reflux disease. Clinical Perspectives in Gastroenterology (1998) Sept. :28–39
   Google Scholar
• FORD GA, OLIVER PS, PRIOR JS et al: Omeprazole in the treatment of asthmatics with nocturnal symptoms and gastro-esophageal reflux: a placebo-controlled cross-over study. Postgrad. Med. J. (1994) 7 0 (823):350–354.
   Google Scholar
• METER JH, MCNALLY PR, PUNJA M et al: Does omepra-zole (Prilo sec) improve respiratory function in asthmatics with gastroesophageal reflux? A double-blind, placebo-controlled crossover study. Dig. Dis. ScL (1994) 39(102127–2133.
   Google Scholar
• HARDING SM, RICHTER JE, GUZZO MR et al.: Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am. J. Med. (1996) 100 (4):395–405.
   PubMedGoogle Scholar
• BOEREE MJ, PETERS FTM, POSTMA DS, KLEIBERBEUKER JH: Effect of high dose omeprazole on airway hyperre-sponsiveness and pulmonary function in patients with obstructive lung disease. Gastroenterology (1995) 1 08:A61.
   Google Scholar
• LEVIN TR, SPERLING RM, MCQUAID KR: Omeprazole improves peak expiratory flow rate and quality of life in asthmatics with gastroesophageal reflux. Am. J Gastroenterol. (1998) 93 (7):1060–1063.
   PubMedGoogle Scholar
• KAMEL PL, HANSON D, KAHRILAS PJ: Omeprazole for the treatment of posterior laryngitis. Am. J. Med. (1994) 96 (4):321–326.
   PubMedGoogle Scholar
• JASPERSEN D, WEBER R, DRAF W, HAMMAR C-H: Omeprazole for the treatment of reflux associated chronic laryngitis. Gastroenterology (1996) 11 0:A143. Abstract.
   Google Scholar
• HANSON DG, KAMEL PL, KAHRILAS PJ: Outcomes of antireflux therapy for the treatment of chronic laryngitis. Ann. Otol. Rhino]. Laryngol. (19 9 5) 1 04 (7):550–555.
   Google Scholar
• OURS TM, KAVURA MS, SCHILZ RJ, RICHTER JE: A prospective evaluation of esophageal testing and a double- blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. Am. J. Gastroenterol. (1999) 94 (10 :3132–38.
   Google Scholar
• ACHEM SR, KOLTS BE, WEARS R et al.: Chest pain associ-ated with nutcracker esophagus: a preliminary study of the role of gastroesophageal reflux. Am. J. Gastroen-terol. (1993) 88(2):187–192.
   PubMedGoogle Scholar
• ACHEM SR, KOLTS BE, MACMATH T et al.: Effects of omeprazole versus placebo in treatment of non-cardiac chest pain and gastroesophageal reflux. Dig. Dis. ScL (1997) 42 (102138–2145.
   Google Scholar
• FASS R, FENNERTY MB, OFMAN JJ et al: The clinical and economic value of a short course of omeprazole in patients with non-cardiac chest pain. Gastroenterology (1998) 115:42–49.
   PubMed Web of Science ®Google Scholar
• OFMAN JJ, GRALNEK IM, UDANI J et al.: The cost-effectiveness of the omeprazole test in patients with non-cardiac chest pain. Am. J Medicine (1999) 107:219–227.
   PubMed Web of Science ®Google Scholar
• COLIN-JONES DG: Safety of lansoprazole. Aliment. Pharmacol. Ther. (1993) 7 (Suppl. 0:56–60. Discussion 61–66.
   Google Scholar
• NELIS GF: Safety profile of omeprazole: adverse events with short-term treatment. Digestion (1989) 44 (Suppl. 1):68–76.
   Google Scholar
• JOELSON S, JOELSON TB, LUNDBORG P et al: Safety experience from long-term treatment with omepra-zole. Digestion (1992) 51 (Suppl. 0:93–101.
   Google Scholar
• WOLFE MM, SOLL AH: The physiology of gastric acid secretion. N Engl. J. Med. (1988) 319 (26) :1707–1715.
   PubMed Web of Science ®Google Scholar
• JOHNSON D, RIFF R, PERDOMO C et al: Rabeprazole: safety profile of a new proton pump inhibitor. Gastro-enterology (1999) 116:A201. Abstract G0875.
   Google Scholar
• JUDMAIER G, KOELZ HR: Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Pantoprazole-Duodenal Ulcer Study Group. Aliment. Pharmacol. Ther. (1994) 8(1):81–86.
   PubMedGoogle Scholar
• REHNER M, ROHNER HG, SCHEPP W: Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration-a multicenter study. Aliment. Pharmacol. Ther. (1995) 9(0411–416.
   PubMed Web of Science ®Google Scholar
• SCHEPP W, CLASSEN M: Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicenter study. Scand. Gastroenterol (1995) 30(6):511–514.
   PubMed Web of Science ®Google Scholar
• FRESTON JW: long-term acid control and proton pump inhibitors; interactions and safety issues in perspec-tive. Am. J. Gastroenterol (1997) 92 (Suppl. 4):51S-55S. Discussion 55S–57S.
   Google Scholar
• TOLMAN KG: Acid hyposecretory states: consequences of hypochlorhydria. In: Clinical practice of Gastroenter-ology. Current Medicine, Inc, Philadelphia, PA, USA (1999) Ch. 36: 324–330.
   Google Scholar
• BERARDI RR, WELAGE LS: Proton-pump inhibitors in acid-related diseases. Am. J Health Syst. Pharm. (1998) 55(20:2289–2298.
   PubMedGoogle Scholar
• HUMPHRIES TG AND THE RABEPRAZOLE INTERNA-TIONAL PROJECT TEAM: A review of the drug-drug interaction potential of rabeprazole sodium based on CYP 450 interference or absorption effects. World Congress of Gastroenterology. Vienna, Austria (Sept 1998).
   Google Scholar
• CHIN TVV, LOEB M, FONG IW: Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob. Agents. Chemother. (1995) 3 9 (8):1671–1675.
   Google Scholar
• HUMPHRIES TJ, SPERA AC, LAURENT AL et al.: Coadminis-tration of rabeprazole sodium (E3810) and digoxin results in a predictable interaction. Am. J Gastroenterol. (1996) 91:1914. Abstract.
   Google Scholar
• OOSTERHUIS B, JONKMAN JH, ANDERSSON T et al.: Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br. J. Clin. Pharmacol (1991) 3 2 (5):569–572.
   Google Scholar
• HARTMANN M, HUBER R, BLIESATH H et al.: lack of interaction between pantoprazole and digoxin at therapeutic doses in man. In: Management of add-related diseases: focus on pantoprazole. Charite, Berlin, Germany (1993):34–35.Abstracts.
   Google Scholar
• DELHOTAL-LANDES B, COURNOT A, VERMERIE N et al.: The effect of food and antacids on lansoprazole absorption and disposition. Eur. J. Drug Metab. Pharma-cokinel (1991) Special No 3:315–320.
   Google Scholar
• TUYNMAN HA, FESTON HP, ROHSS K et al.: lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules. Br. J. Clin. Pharmacol. (1987) 24(6):833–835.
   PubMedGoogle Scholar
• HARTMANN M, BLIESATH H, HUBER R et al.: lack of influence of antacids on the pharmacokinetics of the new gastric 11±X±-ATPa5e inhibitor pantoprazole. Gastroenterology (1994) 106 (Suppl.):Abstract 91.
   Google Scholar
• SCHENK BE, FESTEN HP, KUIPERS EJ et al.: Effect of shor t-and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment. Pharmacol. Ther. (1996) 1 0 (4): 541–545.
   Google Scholar
• GUGLER R, JENSEN JC: Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology (1985) 89 (6) :1235–1241.
   Google Scholar
• PRICHARD PJ, WALT RP, KITCHINGMAN GK et al.: Oral phenytoin pharmacokinetics during omeprazole therapy. Br. J. Clin. Pharmacol. (1987) 2 4 (4):543–545.
   Google Scholar
• BACHMANN KA, SULLIVAN TJ, JAUREGUI L et al.: Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. Br. Clin. Pharmacol. (1993) 36:380–382.
   PubMedGoogle Scholar
• KOKUFU T, IHARA H, SUGIOKA N et al.: Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur. J. Clin. Pharmacol. (19 9 5) 48 (5):391–395.
   Google Scholar
• GRANNEMAN GR, KAROL MD, LOCKE CS et al.: Pharma-cokinetic interaction between lansoprazole and theophylline. Ther. Drug. Monit. (1995) 17(5):460–464.
   PubMedGoogle Scholar
• DILGER K, ZHENG Z, KLOTZ U: lack of drug interaction between omeprazole,lansoprazole,pantoprazole and theophylline. Br. J. Clin. Pharmacol. (1 9 9 9) 48 (3):438–444.
   Google Scholar
• FITTON A, WISEMAN L: Pantoprazole, a review of its pharmacological properties and therapeutic uses in acid-related disorders. Drugs (1996) 51 (3):460–482.
   PubMedGoogle Scholar
• KUIPERS EJ, LUNDELL L, KLINKENBERG-KNOLL E et al.: Atrophic gastritis and Helkobacter pyloriinfection in patients with reflux esophagitis treated with omepra-zole or fundoplication. N. Engl. J Med. (1996) 334:1018–1027.
   PubMed Web of Science ®Google Scholar
• STOLTE M, BETHKE B, RUHL G et al.: Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z. Gastroenterol. (1992) 30:134–138.
   PubMed Web of Science ®Google Scholar
• RIDDELL RH: The biopsy diagnosis of gastroesophageal reflux disease, `carditis' and Barrett's esophagus and sequellae of therapy. Am. J Surg. Pathol. (1996) 20:31–50.
   PubMedGoogle Scholar
• DRIMAN DK, WRIGHT C, TOUGAS G et al.: Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Dig. Dis. sa (1996) 41 :2039–2047.
   PubMedGoogle Scholar
• KRISHMAMURTHY S, DAYAL Y: Parietal cell protrusions in gastric ulcer disease. Hum. Pathol. (1997) 28:1126–1130.
   PubMedGoogle Scholar
• GRAHAM JR: Gastric polyposis: onset during long-term therapy with omeprazole. Med. J. Aust. (1992) 157:287–288.
   PubMed Web of Science ®Google Scholar
• GRAHAM JR: Omeprazole and gastric polyposis in humans. Gastroenterology (1993) 1 0 4 :1584.
   Google Scholar
• EL-ZIMAITY HM, JACKSON FH, GRAHAM DY: Fundic gland polyps developing during omeprazole therapy. Am. J. Gastroenterol. (1997) 92:1858–1860.
   PubMed Web of Science ®Google Scholar
• VAN VLIERBERGHE H, DEVOS M, DECOCK G et al.: Fun dic gland polyps: Three other case reports suggesting a possible association with acid suppressing therapy. Acta. Gastroenterol. Belg. (1997) 60:240–242.
   PubMedGoogle Scholar
• NAEGELS S, URBAIN D: Omeprazole and fundic gland polyps. Am. J. Gastroenterol. (1998) 93:855.
   PubMedGoogle Scholar
• CHOUDRY U, BOYCE HW Jr., CAPPOLA D: Proton pump inhibitor-associated gastric polyps: a retrospective Exp. Opin. Pharmacother. (2000) 1(6) analysis of their frequency and endoscopic, histologic and ultrastructural characteristics. Am. J Clin. Pathol. (1998) 110:615–621.
   Google Scholar
• DECLICH P, AMBROSIANI P, PRADA A et al.: Fundic metaplasia with parietal cell hyperplasia of the antrum: a lesion possibly associated with long-term use of omsprazole. Am. J. Gastroenterol (1999) 94:2317–2319.
   PubMedGoogle Scholar
• FITZGIBBONS PL, JAMIDAR PA: The effect of long-term acid suppression on gastric mucosal histology. Am. J Pathol. (1998) 110:569–571.
   Google Scholar
• SOLCIA E, VILLANI L, FIOCCA R et al: Effects of eradica-tion of Helkobacter pylori on gastritis in duodenal ulcer patients. Scand. j Gastroenterol. (1994) 29 (Suppl. 201):28–34.
   Google Scholar
• STOLTE M, MEINING A, SCHMITZ JM et al: Changes in Helkobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-eosophageal reflux disease. Aliment. Pharmacol. Ther. (1998) 12:247–253.
   PubMedGoogle Scholar
• MEINING A, BOSSECKERT H, CASPARY WF et al: H2-receptor antagonists and antacids have an aggravating effect on Helkobacter pylori gastritis in duodenal ulcer patients. Aliment. Pharmacol. Ther. (1997) 11 (4):729–734.
   PubMedGoogle Scholar
• JONSSON K, STROM M, BODEMAR G et al.: Histologic changes in the gastroduodenal mucosa after long-term medical treatment with cimetidine or parietal cell vagotomy in patients with juxtapyloric ulcer disease. Scand.J. Gastroenterol. (1988) 23:433–441.
   PubMed Web of Science ®Google Scholar
• CORREA P, HENZEL W, QUELLO C, TANNENBAUM S, ARCHER M: A model for gastric cancer epidemiology. Lancet (1975) 2:58–60.
   PubMed Web of Science ®Google Scholar
• MCCOLL KEL, MURRAY LS, GILLEN D: Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology (2000) 118:239.
   Google Scholar
• POUNDER RE, WILLIAMS MP: Omeprazole and acceler-ated onset of atrophic gastritis (letter). Gastroenterology (2000) 118:238–239.
   PubMedGoogle Scholar
• HACKELSBERGER A, MIEHLKE S, LEN N et al.: Helico-barter pylori eradication vs. short-term acid suppres-sion: long-term consequences for gastric body mucosa. Gastroenterology (1996) 11 0 :A127.
   Google Scholar
• DECLICH P, AMBROSIANI L, PRADA A et al.: Fundic metaplasia with parietal cell hyperplasia of the antrum: a lesion possibly associated with long-term use of omeprazole (letter). Am. J Gastroenterol. (1999) 94:2317–2319.
   PubMedGoogle Scholar
• STOCKBRUEGGER RW: Bacterial overgrowth as a consequence of reduced gastric acidity. Scand. J. Gastroenterol (1985) 111:7–16.
   Google Scholar
• SALTZMAN JR, KOWDLEY KV, PEDROSA MC et al: Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology (1994) 106(3):615–623.
   PubMed Web of Science ®Google Scholar
• ELSBORG L, MOSBECH J: Pernicious anemia as a risk factor in gastric cancer. Acta. Med. Scand. (1979) 206 (4):315–318.
   PubMedGoogle Scholar
• SHARMA BK, SANTANA IA, WOOD EC et al.: Intragastric bacterial activity, and nitrosation before, during and after treatment with omeprazole. Br. Med. J (Clin Res. Ed) (1984) 2 89 (6447):717–719.
   Google Scholar
• KOOP H: Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment.Pharmacol Therap. (1992) 6:399–406.
   PubMed Web of Science ®Google Scholar
• TERMANINI B, GIBFRIL F, SUTLIFF VE et al.: Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am. J. Med. (1998) 104:422–430.
   PubMed Web of Science ®Google Scholar
• KOOP H, BACHEM MG: Serum iron, ferritin and vitamin B12 during prolonged omeprazole therapy. J Clin. Gastroenterol. (1992) 14:288–292.
   PubMed Web of Science ®Google Scholar
• BELLOU A, AIMONE-GASTIN I, DEKORWIN JD et al: Cobalamin deficiency with megaloblastic anemia in one patient under long-term omeprazole therapy. J Intern. Med. (1996) 240:161–164.
   PubMed Web of Science ®Google Scholar
• KITTANG E, AADLAND E, SCHONSBY H: Effect of omeprazole in the secretion of intrinsic factor, gastric acid and pepsin in man. Gut (1985) 26:594–598.
   PubMed Web of Science ®Google Scholar
• SCHENK BE, FESTEN HPM, KUIPERS EJ et al: Effect of short-term treatment with omeprazole on the absorp-tion and serum levels of cobalamin. Aliment. Pharmacol. Therap. (1996) 10:541–545.
   PubMedGoogle Scholar
• HOWDEN CW: Vitamin B12 levels during prolonged treatment with proton pump inhibitors./ Clin. Castro-enterol. (2000) 3 0 (1):29–33.
   Google Scholar
• KITTANG E, SCHONSBY H: Effect of gastric and acidity on the release of cobalamins from food and their subsequent binding to R-protein. Scand. J. Gastroen-terol. (1987) 22:1031–1037.
   PubMed Web of Science ®Google Scholar
• SALTZMAN JR, KEMP JA, GOLNER BB et al.: Effect of hyperchlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. j Am. Coll Nutr. (1994) 13:584–591.
   PubMed Web of Science ®Google Scholar
• WALSH JH: Role of gastrin as a trophic hormone. Digestion (1990) 47 (Suppl. 1):11–16. Discussion 49–52.
   Google Scholar
• BORCH K, RENVALL H, LEIDBERG G: Gastric endocrine cell hyperplasia and carcinoid tumours in pernicious anemia. Gastroenterology (1985) 88(3) :638–648.
   PubMed Web of Science ®Google Scholar
• BARDRAM L, THOMSEN P, STADIL F: Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison Syndrome. Digestion (1986) 35 (Suppl. 0:116–122.
   Google Scholar
• CARLSSON E: A review of the effects of long-term acid inhibition in animals. Scand. j Gastroenterol (1989) (Suppl.) 166:19–23.
   Google Scholar
• LEE AK, DELELLIS RA, BLOUNT M et al: Pituitary proliferative lesions in aging male Long-Evens rats. A model of mixed multiple endocrine neoplasia syndrome. Lab. Invest. (1982) 47(6):595–602. Exp. Opin. Pharmacother. (2000) 1(6)
   Google Scholar
• LEHY T, CADIOT G, MIGNON M et al: Influence of multiple endocrine neoplasia Type I on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut (1992) 33 (9) :1275–1279.
   PubMed Web of Science ®Google Scholar
• LAMBERTS R, CRUETZFELDT W, STRUBER HG et al: ling-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth and gastritis. Gastroen-terology (1993) 104 (5) :1356–1370.
   PubMedGoogle Scholar
• CRUETZFELDT W, LAMBERTS R: Is hypergastrinemia dangerous to man? Scand. J. Gastroenterol. (1991) 26 (Suppl. 180179–191.
   Google Scholar
• SOLCIA E, FIOCCA R, HAVU N et al.: Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion (1992) 51 (Suppl. 1):82–92.
   Google Scholar
• HSING AW, HANSSON LE, MCLAUGHLIN JK et al.: Pernicious anemia and subsequent cancer: A population-based cohert study. Cancer (1993) 71 (3):745–750.
   PubMedGoogle Scholar
• UPP JR Jr., SINGH P, TOWNSEND CM et al: The clinical significance of gastrin receptors in human colon cancers. Gastroenterology (1988) 94:A472.
   Google Scholar
• JONSSON B, STALHAMMAR NO: The cost effectiveness of omeprazole and ranitidine in intermittent and mainte-nance treatment of reflux oesophagitis: the case of Sweden. Br. J. Med. Econ. (1993) 6:111–126.
   Google Scholar
• BATE CM, RICHARDSON PDI: Cost effectiveness of omeprazole in the management of gastroesophageal reflux disease in clinical practice. Br. J Med. Econ. (1994) 7:81–97.
   Google Scholar
• BATE CM, RICHARDSON PDI: Cost effectiveness of 20mg and 40mg of omeprazole in oesophageal reflux disease. Br. J. Med. Econ. (1993) 6:59–66.
   Google Scholar
• BERGMANN JF, HAMELIN B, BARBIER JP: Comparison of the cost-efficacy ratio of omeprazole and ranitidine for treatment of reflux oesophagitis. Gastroenterol. Clin. Biol. (1995) 19(5):482–486.
   PubMedGoogle Scholar
• BLOOM BS, HILLMAN AL, LA MONT B et al.: Omeprazole or ranitidine plus metoclopramide for patients with severe erosive oesophagitis. A cost-effectiveness analysis. Pharmacoeconomics (1995) 8(0343–349.
   Google Scholar
• GREEN JR, BATE CM, COPEMAN MB et al.: A comparison of the cost-effectiveness of omeprazole and ranitidine in reflux oesophagitis. Br. J. Med. Econ. (1995) 8:157–169.
   Google Scholar
• PHILLIPS C, MOORE A: Trial and error- an expensive luxury: economic analysis of effectiveness of proton pump inhibitors and histamine antagonists in treating reflux disease. Br. J. Med. Econ. (1997) 11:55–63.
   Google Scholar
• HILLMAN AL, BLOOM BS, FENDRICK AM et al.: Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Arch. Intern. Med. (1992) 152 (7) :1467–1472.
   PubMedGoogle Scholar
• GERSON LB, ROBBINS AS, GARBER A et al.: A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am. J. Gastroenterol. (2000) 95:395–407.
   PubMed Web of Science ®Google Scholar
• HEUDEBERT GR, MARKS R, WILCOX CM: Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastro-enterology (1997) 112(4):1078–1086.
   PubMedGoogle Scholar